Intangible Assets	9 Months Ended
Sep. 30, 2018
Notes to Financial Statements
Intangible Assets	On December 15, 2017, the Company entered into an agreement with Preprogen, pursuant to which the parties agreed to the sale, assignment, and license-back of certain assets, including intellectual property transferred to Preprogen necessary to the development, manufacture, marketing and sale of the Company’s OTC miniform products for the feminine hygiene and hemorrhoid treatment markets. At September 30, 2018 and December 31, 2017, the Company had reduced its capitalized intangible assets to zero. Amortization expense for the nine months ended September 30, 2018 and 2017 totaled $0 and $2,682, respectively.

Intangible Assets

9 Months Ended

Sep. 30, 2018

On December 15, 2017, the Company entered into an agreement with Preprogen, pursuant to which the parties agreed to the sale, assignment, and license-back of certain assets, including intellectual property transferred to Preprogen necessary to the development, manufacture, marketing and sale of the Company’s OTC miniform products for the feminine hygiene and hemorrhoid treatment markets. At September 30, 2018 and December 31, 2017, the Company had reduced its capitalized intangible assets to zero.

Amortization expense for the nine months ended September 30, 2018 and 2017 totaled $0 and $2,682, respectively.